The government is now operating in accordance with the Guidance on Caretaker Conventions, pending the outcome of the 2025 federal election.
AusPAR: Alemtuzumab (rch)
Australian Public Assessment Report
Device/Product Name
Lemtrada / Remniq
Active ingredients
Alemtuzumab (rch)
AusPAR Date
Published
Sponsor
Submission Number
PM-2012-02297-3-1
Submission Type
New dosage strength, New patient group, New dosage regime
Decision
Approved